The incidence of chronic obstructive pulmonary disease (COPD) is rising in the United
States, and the disease represents a significant source of morbidity and mortality. Primary …

Most patients with COPD are recommended to initiate maintenance therapy with a single
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …

Background: This study compared real-world patient-reported outcomes (PROs) measured
by the Clinical COPD Questionnaire (CCQ), the London Chest Activities of Daily Living …

Inhaled bronchodilator medications are central to the management of COPD and are
frequently given on a regular basis to prevent or reduce symptoms. While short-acting …

The Global Obstructive Lung Disease (GOLD) guidelines suggest the potential use of
combination bronchodilator therapy in patients with stage II or higher chronic obstructive …

New guidelines emphasize combination bronchodilators as a mainstay of therapy for many
patients with symptomatic COPD and there are several new combination bronchodilator …

Background No observational studies have evaluated the “real-world” effectiveness of dual
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …

Pharmacological medications used for the treatment of COPD patients have increased
significantly. Long-acting bronchodilators have been recognized as the mainstay of the …

Background Several new fixed-dose combination bronchodilators have been recently
launched, and assessing their efficacy relative to each other, and with open dual …

In this guideline update, we highlight important and new findings related to pharmacological
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …